Vaccinex jumps on promising early data for cancer drug

Vaccinex

26/01/2022 15:10

** Drug developer's shares  VCNX.O  up 22.5% at $1.25 
    ** Co says two of three patients enrolled in a phase 1 trial
of its experimental drug did not have any detectable signs of
cancer after treatment with the drug in combination with Merck's
 MRK.N  Keytruda  urn:newsml:reuters.com:*:nGNXy2Zkd
    ** Phase 1 trials are not meant to measure efficacy of
drugs, and mostly used to test a drug's safety in patients
    ** Drug was being tested in patients with head and neck
cancer 
    ** Including session gains, stock has fallen ~52% in the
past 12 months 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))